Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Risk-adapted strategy in HR+/HER2 negative early breast cancer

Defining the risk from clinical assessment to genomic classifiers: Does ethnicity matter?

Date

02 Dec 2022

Session

Risk-adapted strategy in HR+/HER2 negative early breast cancer

Topics

Tumour Site

Breast Cancer

Presenters

Yoon Sim Yap

Authors

Y.S. Yap

Author affiliations

  • Medical Oncology, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.